Harvey M. Golomb to Drug Evaluation
This is a "connection" page, showing publications Harvey M. Golomb has written about Drug Evaluation.
Connection Strength
0.111
-
5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer. Cancer. 1990 Aug 01; 66(3):437-42.
Score: 0.024
-
Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. J Natl Cancer Inst. 1989 Aug 02; 81(15):1172-4.
Score: 0.022
-
Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest. 1989 Jul; 96(1):110-3.
Score: 0.022
-
Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma. Cancer Treat Rep. 1987 Mar; 71(3):311-2.
Score: 0.019
-
Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol. 1991 May; 9(5):754-61.
Score: 0.006
-
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8.
Score: 0.006
-
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol. 1988 Nov; 6(11):1714-21.
Score: 0.005
-
Trial of vindesine, etoposide, and cisplatin in patients with previously treated, advanced-stage, non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1984 Feb; 68(2):413-5.
Score: 0.004
-
Mitoxantrone in malignant lymphomas. Cancer Treat Rev. 1983 Dec; 10 Suppl B:69-72.
Score: 0.004